南京生物医药谷50余项产品技术国内外首创 以创新为引擎 全速竞逐医药新赛道 "未来10年，对于脑科学领域是个机遇，比如脑卒中患者有语言障碍，只要戴上一顶'魔法帽'，他的想 法就能变成文字显示出来，这也是我们中心正在孵化的'汉语魔法帽'项目。"程和平院士介绍。 早在今年3月，江北新区揭牌成立"江苏省类脑智能技术创新中心"。该中心由北京大学分子医学南京转 化研究院牵头，联合南京医科大学、南京脑科医院等多方资源，计划用5年时间突破一批前沿科技成 果。 不仅是脑科学领域，在基因与细胞治疗、器官芯片等前沿赛道上，南京生物医药谷也在加速布局，比如 在基因与细胞治疗方面，已打造了涵盖基因检测、诊断、试剂、免疫细胞治疗、CAR-T细胞治疗的全产 业链。本月初，园区企业尧唐生物宣布完成超3亿元B轮融资，公司首席技术官王子君博士表示："处在 药谷这样的产业集群之中，为企业发展带来了很多助力，尧唐生物也得以快速发展。" □ 南京日报/紫金山新闻记者 李都 通讯员 钱钰玲 全球首款全人源BCMA CAR-T细胞治疗1类新药福可苏、全球首创"硒代技术"的1类抗流感新药济可 舒、全球首个且唯一获得NMPA、FDA、CE认证的肿瘤NGS大 ...

Core Viewpoint - The seventh Pharmaceutical Frontier Academic Forum emphasizes the importance of original drug development and the role of artificial intelligence in accelerating the drug research and development process [1] Group 1: Forum Highlights - The forum, held in Nanjing, focuses on cutting-edge areas such as gene and cell therapy, advanced formulations and delivery technologies, and AI in new drug development [1] - Experts discuss the collaborative development path from source innovation to clinical transformation [1] Group 2: Key Statements - Chen Kaixian, the forum chairman and an academician of the Chinese Academy of Sciences, highlights that developing original new drugs is crucial for building new productive forces in biomedicine and achieving a strong technological nation in this field [1] - The use of artificial intelligence is noted as a key technology in drug research, with an example of an AI chemist at the University of Liverpool working 21.5 hours a day [1] - Future advancements are expected in automated molecular manufacturing, automated biological laboratories, and virtual clinical laboratories, leading to efficient and precise synthesis and continuous manufacturing of drug molecules [1]

Core Viewpoint - The report highlights the financial performance and strategic initiatives of Suzhou Novoprotein Scientific Inc. for the first half of 2025, emphasizing its focus on innovation and market adaptation in the biopharmaceutical sector [4][6]. Financial Performance - The company's revenue for the first half of 2025 was approximately 72.09 million RMB, representing a 20.85% increase compared to 59.66 million RMB in the same period last year [5]. - The total profit for the period was a loss of approximately 28.92 million RMB, compared to a loss of 16.48 million RMB in the previous year [5]. - The net profit attributable to shareholders was approximately -24.22 million RMB, compared to -8.91 million RMB in the same period last year [5]. - The net cash flow from operating activities was -14.08 million RMB, a significant decrease from 23.30 million RMB in the previous year, reflecting a 160.45% decline [5]. Business Overview - The company specializes in the research, development, production, and sales of target and factor proteins, recombinant antibodies, enzymes, and reagents, providing comprehensive solutions in biopharmaceuticals, in vitro diagnostics, and life sciences [6][8]. - The company has developed a total of 3,566 types of target and factor proteins, focusing on areas such as oncology, metabolism, and autoimmune diseases [8][9]. - The company has 166 types of recombinant antibodies, which are used in immunodiagnostic reagents, new vaccines, and antibody drugs [9]. Strategic Initiatives - The company is actively engaging in gene and cell therapy, leveraging its GMP production technology to provide tools and solutions for gene editing [6][8]. - The company is enhancing its RNA production processes and expanding its product offerings in RNA applications to meet diverse customer needs [6][8]. - The company aims to address the "bottleneck" issues in basic biopharmaceutical raw materials by integrating its seven comprehensive technology platforms and 23 core technologies [8]. Industry Context - The Chinese government is promoting the integration of biotechnology and information technology, aiming to strengthen the biopharmaceutical industry and support innovation in drug development [7][8]. - Recent government initiatives, including the "High-Quality Development Action Plan for the Pharmaceutical Industry," are expected to boost confidence in the pharmaceutical sector and support the development of innovative drugs [7].